Measurement of Disease Activity and Damage in Sjögren's Syndrome

Rheumatic Disease Clinics of North America

Volumn 34, Issue 4, 2008, Pages 963-971

  Vitali, Claudio ^a  

^a 'Villamarina' Hospital   (Italy)

Author keywords

Disease activity; Disease damage; Outcome measures; Sj gren's syndrome

Indexed keywords

ARTIFICIAL TEAR; CD20 ANTIBODY; CORTICOSTEROID; IMMUNOSUPPRESSIVE AGENT; MONOCLONAL ANTIBODY; MUSCARINIC AGENT; SALIVA SUBSTITUTE; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

CLINICAL ASSESSMENT; CLINICAL FEATURE; CLINICAL TRIAL; DISEASE ACTIVITY; DISEASE COURSE; HUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RATING SCALE; REVIEW; SJOEGREN SYNDROME; TREATMENT OUTCOME;

AUTOIMMUNE DISEASES; HUMANS; OUTCOME ASSESSMENT (HEALTH CARE); RECOVERY OF FUNCTION; RECURRENCE; SEVERITY OF ILLNESS INDEX; SJOGREN'S SYNDROME;

EID: 54849407628     PISSN: 0889857X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.rdc.2008.08.002     Document Type: Review

References (24)

1. Symmonds D.P.M. Disease assessment indices: activity, damage and severity. Ballieres Clin Rheumatol 9 2 (1995) 267-285
2. Fries J.F., Hochberg M.C., and Medsger T.A. Criteria for rheumatic diseases: different types and different functions. Arthritis Rheum 37 4 (1994) 454-462
3. Liang M.H. Translating outcomes measurement in experimental therapeutics of systemic rheumatic disease to patient care. Rheum Dis Clin North Am 32 1 (2006) 1-8
4. Pincus T., and Sokka T. Complexities in the quantitative assessment of patients with rheumatic diseases in clinical trials and clinical care. Clin Exp Rheumatol 23 Suppl 39 (2005) S1-S9
5. Liang M.H., Socher S.A., Neal Roberts W., et al. Measurement of systemic lupus erythematosus activity in clinical research. Arthritis Rheum 31 7 (1988) 817-825
6. American College of Rheumatology Ad Hoc Committee on Systemic Lupus Erythematosus Response Criteria. The American College of Rheumatology response criteria for systemic lupus erythematosus clinical trials: measures of overall disease activity. Arthritis Rheum 50 11 (2004) 3418-3426
7. Pincus T., and Sokka T. Quantitative measures for assessing rheumatoid arthritis in clinical trials and clinical care. Best Pract Res Clin Rheumatol 17 5 (2003) 753-781
8. Strand V., Gladman D., Isenberg D., et al. Outcome measures to be used in clinical trials in systemic lupus erythematosus. J Rheumatol 26 2 (1999) 490-497
9. Valentini G., Della Rossa A., Bombardieri S., et al. European multicentre study to define disease activity criteria for systemic sclerosis. II. Identification of disease activity variables and development of preliminary activity indexes. Ann Rheum Dis 60 6 (2001) 592-598
10. Gladman D., Ginzler E., Goldsmith C., et al. The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus. Arthritis Rheum 39 3 (1996) 363-369
11. van der Heijde D. How to read radiographs according to the Sharp/van der Heijde method. J Rheumatol 27 1 (2000) 261-263
12. Mitsias D.I., Kapsogeorgou E.K., and Moutsopoulos H.M. Sjögren's syndrome: why autoimmune epithelitis?. Oral Dis 12 6 (2006) 523-532
13. Garcia-Carrasco M., Ramos Casals M., Rasas J., et al. Primary Sjögren's syndrome: clinical and immunologic disease patterns in a cohort of 400 patients. Medicine (Baltimore) 81 4 (2002) 270-280
14. Ioannidis J.P., Vassiliou V.A., and Moutsopoulos H.M. Long term risk of mortality and lymphoproliferative diseases and predictive classification of primary Sjögren's syndrome. Arthritis Rheum 46 3 (2002) 741-747
15. Ramos-Casals M., and Brito-Zeron P. Emerging biological therapies in primary Sjögren's syndrome. Rheumatology (Oxford) 46 9 (2007) 1389-1396
16. Looney R.J. Will targeting B cells be the answer for Sjögren's syndrome?. Arthritis Rheum 56 5 (2007) 1371-1377
17. Seror R., Sordet C., Guillevin L., et al. Tolerance and efficacy of rituximab and changes in serum B cell biomarkers in patients with systemic complications of primary Sjögren's syndrome. Ann Rheum Dis 66 3 (2007) 351-357
18. Szororay P., and Jonnson R. The BAFF/APRIL system in systemic autoimmune diseases with special emphasis on Sjögren's syndrome. Scand J Immunol 62 5 (2005) 421-428
19. Vitali C., Palombi G., Baldini C., et al. Sjögren's syndrome disease damage index and disease activity index. Scoring systems for the assessment of disease damage and disease activity in Sjögren's syndrome, derived from an analysis of a cohort of Italian patients. Arthritis Rheum 56 7 (2007) 2223-2231
20. Vitali C., Bencivelli W., Isenberg D.A., et al. Disease activity in systemic lupus erythematosus: report of the Consensus Study Group of the European Workshop for Rheumatology Research. II Identification of the variables indicative of disease activity and their use in the development of an activity score. Clin Exp rheumatol 10 5 (1992) 541-547
21. Bowman S.J., Sutcliffe N., Isenberg D.A., et al. Sjögren's Syndrome Clinical Activity Index (SCAI)-a systemic disease activity measure for use in clinical trials in primary Sjögren's syndrome. Rheumatology (Oxford) 46 12 (2007) 1845-1851
22. Hay E.M., Bacon P.A., Gordon C., et al. The BILAG index: a reliable and valid instrument for measuring clinical disease activity in systemic lupus erythematosus. Q J Med 86 7 (1993) 447-458
23. Sutcliffe N., Stoll T., Pyke S., et al. Functional disability and end organ damage in patients with systemic lupus erythematosus (SLE), SLE and Sjögren's syndrome (SS), and primary SS. J Rheumatol 25 1 (1998) 63-68
24. Barry RJ, Sutcliffe N, Isenberg DA, et al. The Sjögren's syndrome Damage Index (SSDI)-a damage index for use in clinical trials and observational studies in primary Sjögren's syndrome. Rheumatology 2008;47(8):1193-8.